Evidence map›Paper›PMID 41272035›Full record

ArticleScientific reports2025

Unbiased assessment of 2-arachidonoylglycerol in cardiovascular inflammation.

Moritz Nöthel, Franziska Dorer, Alexandru Odainic, Carolyn Krause, Marie Rüthing, Jasper Spitzer, Ulrike Strube, Theresia Weise, Dieter Lütjohann, Georg Nickenig and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Moritz NöthelDepartment of Internal Medicine II, Cardiology, Pneumology, Angiology, University Hospital Bonn, Venusberg-Campus 1, Building 13, 53127, Bonn, Germany. moritz.noethel@ukbonn.de.ORCID http://orcid.org/0000-0002-1620-4492
Franziska DorerMedical Faculty, Institute of Innate Immunity, University of Bonn, 53127, Bonn, NRW, Germany.
Alexandru OdainicDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, 3000, Australia.
Carolyn KrauseDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, 3000, Australia.
Marie RüthingInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127, Bonn, Germany.
Jasper SpitzerInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127, Bonn, Germany.
Ulrike StrubeInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127, Bonn, Germany.
Theresia WeiseDepartment of Internal Medicine II, Cardiology, Pneumology, Angiology, University Hospital Bonn, Venusberg-Campus 1, Building 13, 53127, Bonn, Germany.
Dieter LütjohannInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127, Bonn, Germany.
Georg NickenigDepartment of Internal Medicine II, Cardiology, Pneumology, Angiology, University Hospital Bonn, Venusberg-Campus 1, Building 13, 53127, Bonn, Germany.
Susanne V Schmidt *Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127, Bonn, Germany.ORCID http://orcid.org/0000-0001-9561-2752
Julian Jehle *Department of Internal Medicine II, Cardiology, Pneumology, Angiology, University Hospital Bonn, Venusberg-Campus 1, Building 13, 53127, Bonn, Germany.ORCID http://orcid.org/0000-0002-2719-9692

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

2-arachidonoylglycerol (2-AG) is an endogenous modulator of inflammatory processes. Recent studies demonstrate its key role in inflammatory cardiovascular diseases, such as atherosclerosis and left ventricular remodelling. However, whether 2-AG acts as a pro- or anti-inflammatory agent in cardiovascular inflammation is a matter of controversial debate. CD14

Indexed as

Arachidonic AcidsEndocannabinoidsGlyceridesInflammationAgedCells, CulturedCytokinesFemaleHumansMaleMiddle AgedMonocytesNF-kappa BOsteopontinSignal TransductionTumor Necrosis Factor-alphaArachidonic AcidsCytokinesEndocannabinoidsGlyceridesglyceryl 2-arachidonateNF-kappa BOsteopontinTumor Necrosis Factor-alpha2-arachidonoylglycerolAcute coronary syndromeCoronary heart diseaseEndocannabinoid systemInflammationMonocytes

Identifiers

PMID41272035
PMCPMC12645022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.